Synovial Sarcoma Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Takara Bio, C4 Therapeutics

The Synovial Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Synovial Sarcoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Synovial Sarcoma Market.

Some of the key takeaways from the Synovial Sarcoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Synovial Sarcoma treatment therapies with a considerable amount of success over the years. 
• Synovial Sarcoma companies working in the treatment market are OncoTherapy Science, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., Advenchen Laboratories, Philogen, Nanobiotix, Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, Foghorn Therapeutics Inc., and others, are developing therapies for the Synovial Sarcoma treatment 
• Emerging Synovial Sarcoma therapies such as – OTSA101, CAB-AXL-ADC, NY-ESO-1, CFT – 8634, Afamitresgene autoleucel, Tazemetostat, AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Lurbinectedin, FHD-609, and others are expected to have a significant impact on the Synovial Sarcoma market in the coming years.   
• In May 2023, In order to examine the efficacy and safety of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive individuals aged 2 to 21 with advanced malignancies, Adaptimmune will begin a Phase I/II paediatric basket study
• In October 2022, The Spanish Agency for Medicines and Health Products (Agencia Espanola de Medicamentos y Productos Sanitarios, AEMPS) has approved a Phase 1b/randomized Phase 2 study comparing the effectiveness of doxorubicin alone versus doxorubicin plus LB-100, the company’s lead clinical compound, for the initial treatment of advanced soft tissue sarcomas (ASTS).
• In September 2022, In order to facilitate an investigator-initiated open-label Phase II clinical trial, Immutep Limited is happy to announce that it has executed a Material Transfer Agreement (“Agreement”) with the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Up to 40 patients with select soft tissue sarcoma (STS) will participate in the trial to assess Immutep’s principal product candidate, efti, in combination with pembrolizumab and radiation in the neoadjuvant situation (before to surgery).
• In July 2020, the EMA granted Afamitresgene Autoleucel PRIME status for the treatment of Synovial Sarcoma. ADP-A2M4 to treat synovial sarcoma has been given the FDA Regenerative Medicine Advanced Therapy (RMAT) designation, according to an announcement made by Adaptimmune Therapeutics plc in December 2019

Synovial Sarcoma Overview

Soft tissue sarcomas (STS) have a special subtype known as synovial sarcomas (SS), which make up between 5 and 10% of all STS. The clinical appearance and very early age upon diagnosis set synovialsarcoma apart from other STS. Unique genomic features of synovial sarcomas are caused by a pathognomonic t(X;18) chromosomal translocation, which leads to the development of the SS18:the oncogenes SSX.

Get a Free Sample PDF Report to know more about Synovial Sarcoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight

Emerging Synovial Sarcoma Drugs Under Different Phases of Clinical Development Include:

• OTSA101: OncoTherapy Science
• CAB-AXL-ADC: BioAtla, Inc.
• CFT 8634: C4 Therapeutics
• FHD 609: Foghorn Therapeutics
• BA-3011: BioAtla
• NY-ESO-1: Takara Bio
• CFT – 8634: C4 Therapeutics
• Afamitresgene autoleucel: Adaptimmune
• Tazemetostat: Epizyme, Inc.

Route of Administration

Synovial Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Synovial Sarcoma Pipeline Therapeutics Assessment

• Synovial Sarcoma Assessment by Product Type
• Synovial Sarcoma By Stage and Product Type
• Synovial Sarcoma Assessment by Route of Administration
• Synovial Sarcoma By Stage and Route of Administration
• Synovial Sarcoma Assessment by Molecule Type
• Synovial Sarcoma by Stage and Molecule Type

DelveInsight’s Synovial Sarcoma Report covers around 14+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Synovial Sarcoma product details are provided in the report. Download the Synovial Sarcoma pipeline report to learn more about the emerging Synovial Sarcoma therapies

Some of the key companies in the Synovial Sarcoma Therapeutics Market include:

Key companies developing therapies for Synovial Sarcoma are – dvenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus,  C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals,  Lyell Immunopharma, Telix Pharmaceuticals, and others.

Synovial Sarcoma Pipeline Analysis:

The Synovial Sarcoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Synovial Sarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma Treatment.
• Synovial Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Synovial Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Synovial Sarcoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Synovial Sarcoma drugs and therapies

Synovial Sarcoma Pipeline Market Drivers

• Increasing Incidence of Synovial Sarcoma, increasing research and development activities for the development of targeted therapies are some of the important factors that are fueling the Synovial Sarcoma Market.

Synovial Sarcoma Pipeline Market Barriers

• However, lack of approved therapies, adverse effects associated with the drugs and other factors are creating obstacles in the Synovial Sarcoma Market growth.

Scope of Synovial Sarcoma Pipeline Drug Insight    

• Coverage: Global
• Key Synovial Sarcoma Companies: OncoTherapy Science, BioAtla, Inc., Takara Bio, C4 Therapeutics, Adaptimmune, Epizyme, Inc., Advenchen Laboratories, Philogen, Nanobiotix, Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, Foghorn Therapeutics Inc., and others
• Key Synovial Sarcoma Therapies: OTSA101, CAB-AXL-ADC, NY-ESO-1, CFT – 8634, Afamitresgene autoleucel, Tazemetostat, AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Lurbinectedin, FHD-609, and others
• Synovial Sarcoma Therapeutic Assessment: Synovial Sarcoma current marketed and Synovial Sarcoma emerging therapies
• Synovial Sarcoma Market Dynamics: Synovial Sarcoma market drivers and Synovial Sarcoma market barriers 

Request for Sample PDF Report for Synovial Sarcoma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services